83 Results for "

chimeric humanization

" in MedChemExpress (MCE) Product Catalog:
Products (83)

83 Results for "chimeric humanization" in MCE Product Catalog:

Cat. No.: HY-P99453
CAS No.: 1826819-57-1

Target:  

ADC Antibodies

Research Areas:  

Cancer

Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
loading...
    loading...
Cat. No.: HY-P99470
CAS No.: 2109730-69-8
Synonyms: GEN1029

Target:  

TNF Receptor Apoptosis

Research Areas:  

Cancer

Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .
loading...
    loading...
Cat. No.: HY-P99740
CAS No.: 2229859-11-2

Research Areas:  

Cancer

Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
loading...
    loading...
Cat. No.: HY-P99562
CAS No.: 2148354-90-7
Synonyms: XmAb-18087

Target:  

CD3

Research Areas:  

Cancer

Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .
loading...
    loading...
Cat. No.: HY-P990920
CAS No.: 2851862-91-2
Synonyms: MK-6070; HPN328

Target:  

CD3

Research Areas:  

Cancer

HY-P990920 is an CD3E/ALB/DLL3-targeting (scFv-heavy-lamdba)-VH-VH' type chimeric humanized antibody .
loading...
    loading...
Cat. No.: HY-P990012
CAS No.: 2744320-12-3
Synonyms: EBI-031

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Vamikibart (EBI-031) is a humanized IgG2κ monoclonal antibody targeting IL-6, with high binding affinity for IL-6 and the IL-6/IL-6R complex. Vamikibart reduces central retinal thickness, resolves intraretinal and subretinal foveal fluid, and decreases the levels of intraocular inflammatory markers. Vamikibart can be used in studies of uveitic macular edema (UME) secondary to non-infectious uveitis .
loading...
    loading...
Cat. No.: HY-P99369
CAS No.: 2187368-16-5
Synonyms: IPH 4102; Anti-KIR3DL2/CD158k Reference Antibody (lacutamab)

Target:  

MHC

Research Areas:  

Cancer

Lacutamab (IPH 4102) is a humanized monoclonal antibody targeting KIR3DL2/CD158k, which eliminates KIR3DL2-expressing cells via antibody-dependent cellular cytotoxicity and phagocytosis. Lacutamab is applicable to research related to mycosis fungoides, relapsed or refractory peripheral T-cell lymphoma, and relapsed or refractory cutaneous T-cell lymphoma .
loading...
    loading...
Cat. No.: HY-P99404
CAS No.: 2084037-83-0
Synonyms: E6011

Target:  

CXCR

Research Areas:  

Inflammation/Immunology Cancer

Quetmolimab (E6011) is a humanized anti-Fractalkine (CX3CL1) monoclonal antibody. Quetmolimab binds to membrane-bound and soluble Fractalkine, neutralizes Fractalkine-induced migration of CX3CR1-expressing cells, mediates target-bound complex elimination from serum. Quetmolimab suppresses free soluble Fractalkine levels in cynomolgus monkeys, with target engagement linked to increased serum total Fractalkine concentration. Quetmolimab can be used for the research of Crohn’s disease, rheumatoid arthritis, and primary biliary cholangitis .
loading...
    loading...
Cat. No.: HY-P99822
CAS No.: 2361290-85-7
Synonyms: SHR-1209

Target:  

PCSK9

Research Areas:  

Metabolic Disease

Recaticimab (SHR-1209) is a humanized IgG1 mAb that selectively targets PCSK9. Recaticimab reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), triglyceride (TG), and lipoprotein(a) levels. Recaticimab can be used for hyperlipidemia research .
loading...
    loading...
Cat. No.: HY-P99941
CAS No.: 2079108-44-2
Synonyms: INCMGA-00012; MGA-012

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
loading...
    loading...
Cat. No.: HY-P99523
CAS No.: 2413453-53-7
Synonyms: AMG 199

Target:  

CD3

Research Areas:  

Cancer

Vepsitamab (AMG 199) is a bispecific T-cell engager (HLE BiTE) that binds to MUC17 and CD3. Vepsitamab directs CD3-positive cells to target MUC17-positive cells. Vepsitamab induces cell activation and proliferation. Vepsitamab is applicable to research related to gastric cancer and gastroesophageal junction (g/gej) cancer .
loading...
    loading...
Cat. No.: HY-P99757
CAS No.: 2278244-14-5
Synonyms: Hu3F8-BsAb

Target:  

CD3

Research Areas:  

Cancer

Nivatrotamab (Hu3F8-BsAb) is a bispecific antibody targeting GD2 and CD3, with KD values of 5.8 nM and 194 nM, respectively. Nivatrotamab redirects T cells to tumor sites and activates immune synapses, thereby mediating antibody-dependent T cell-mediated cytotoxicity. Nivatrotamab induces specific tumor cytotoxicity, stimulates the release of Th1 cytokines and promotes immune cell infiltration into tumors. In addition, its Fc segment deglycosylation design effectively prevents complement activation and cytokine storm. Nivatrotamab can be widely used in research related to various solid tumors, including melanoma, neuroblastoma, osteosarcoma, small cell lung cancer, breast cancer, Ewing's sarcoma, colon cancer, ovarian cancer and rhabdomyosarcoma .
loading...
    loading...
Cat. No.: HY-P99776
CAS No.: 2138442-31-4
Synonyms: XmAb-13676
Target:  

CD20 CD3

Research Areas:  

Cancer

Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 + expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
loading...
    loading...
Cat. No.: HY-P991046

Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Donanemab (Mouse IgG2b) is a chimeric antibody composed of humanized variable regions and a mouse IgG2b backbone. Donanemab (Mouse IgG2b) is an anti-amyloid inhibitor used in Alzheimer's disease research.
loading...
    loading...
Cat. No.: HY-P99211
CAS No.: 881191-44-2
Synonyms: ChAglyCD3; TRX 4

Target:  

CD3

Research Areas:  

Metabolic Disease

Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes .
loading...
    loading...
Cat. No.: HY-P99393
CAS No.: 1635395-25-3
Synonyms: MEDI 0562; Tavolimab

Target:  

TNF Receptor

Research Areas:  

Cancer

Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research .
loading...
    loading...
Cat. No.: HY-P99652
CAS No.: 2428381-52-4
Synonyms: AK 111

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.
loading...
    loading...
Cat. No.: HY-P99659
CAS No.: 2102543-86-0
Synonyms: ANB 019

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases .
loading...
    loading...
Cat. No.: HY-P99727
CAS No.: 2419087-89-9
Synonyms: CTB012

Target:  

RABV

Research Areas:  

Infection

Mazorelvimab (CTB012) is an anti-rabies humanized IgG1κ monoclonal antibody that binds to the non-overlapping epitopes on the rabies virus (RABV) glycoprotein. Mazorelvimab binds to highly discontinuous conserved residues that are not in or near antigenic site III. Mezagitamab has potential application in the prevention of rabies .
loading...
    loading...
Cat. No.: HY-P99959
CAS No.: 2379805-59-9
Synonyms: MT-3921; rH116A3

Target:  

TGF-β Receptor

Research Areas:  

Neurological Disease

Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments .
loading...
    loading...